Timessquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.a. (stvn)

In its first-quarter 2026 investor letter, TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted Stevanato Group S.p.A. (NYSE:STVN) Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integra

In its first-quarter 2026 investor letter, TimesSquare Capital U.S.

Mid Cap Growth Strategy highlighted Stevanato Group S.p.A. (NYSE:STVN)

Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integrated solutions for the biopharma and healthcare industries. On June 30, 2026, Stevanato Group S.p.A. (NYSE:STVN) closed at $18.07 per share. One-month return of Stevanato Group S.p.A. (NYSE:STVN) was -2.48%, and its shares lost 26.18% over the past 52 weeks.

Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of about $4.93 billion. TimesSquare Capital U.S. Mid Cap Growth Strategy stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q1 2026 investor letter: “Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers.

Leave a Reply

Your email address will not be published. Required fields are marked *